Booster vaccination with a fractional dose of an oral cholera vaccine induces comparable vaccine-specific antibody avidity as a full dose: A randomised clinical trial

Vaccine ◽  
2020 ◽  
Vol 38 (3) ◽  
pp. 655-662
Author(s):  
Lynda Mottram ◽  
Anna Lundgren ◽  
Ann-Mari Svennerholm ◽  
Susannah Leach
Keyword(s):  
Clinical Trial ◽  
Specific Antibody ◽  
Booster Vaccination ◽  
Randomised Clinical Trial ◽  
Cholera Vaccine ◽  
Antibody Avidity ◽  
Full Dose ◽  
Fractional Dose ◽  
Oral Cholera Vaccine

scholarly journals Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial

Vaccine ◽  
2019 ◽  
Vol 37 (11) ◽  
pp. 1389-1397 ◽  
Author(s):  
James M. McCarty ◽  
Michael D. Lock ◽  
Sean Bennett ◽  
Kristin M. Hunt ◽  
Jakub K. Simon ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Cholera Vaccine ◽  
Randomized Controlled Clinical Trial ◽  
Randomized Controlled ◽  
Age Related ◽  
Oral Cholera Vaccine

scholarly journals Safety and Immunogenicity Assessment of an Oral Cholera Vaccine through Phase I Clinical Trial in Korea

2014 ◽  
Vol 29 (4) ◽  
pp. 494 ◽  
Author(s):  
Young Ok Baik ◽  
Seuk Keun Choi ◽  
Jae Woo Kim ◽  
Jae Seung Yang ◽  
Ick Young Kim ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase I ◽  
Phase I Clinical Trial ◽  
Cholera Vaccine ◽  
Oral Cholera Vaccine ◽  
Immunogenicity Assessment

scholarly journals Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139

mSphere ◽  
2021 ◽  
Author(s):  
Mohammad Kamruzzaman ◽  
Meagan Kelly ◽  
Richelle C. Charles ◽  
Jason B. Harris ◽  
Stephen B. Calderwood ◽  
...  
Keyword(s):  
Vibrio Cholerae ◽  
Specific Antibody ◽  
Cholera Vaccine ◽  
Conjugate Vaccines ◽  
Content Type ◽  
Oral Cholera Vaccine ◽  
Vibrio Cholerae O139 ◽  
Specific Polysaccharide

Cholera is a severe dehydrating illness of humans caused by Vibrio cholerae serogroup O1 or O139. Protection against cholera is serogroup specific, and serogroup specificity is defined by O-specific polysaccharide (OSP).

Sign in / Sign up

Export Citation Format

Share Document